Datum | Källa | Rubrik | Typ | Alternativ |
---|---|---|---|---|
2024-06-14 | Biosergen | Bulletin from the annual general meeting on June 14, 2024 in Biosergen AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-06-12 | Biosergen | Biosergen AB: Biosergen to welcome two new board members based on election at the Annual General Meeting | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-06-11 | Carlsquare | Carlsquare: Final permission received, BSG005 to reach patients | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-06-11 | Biosergen | Biosergen AB: Biosergen receives the final permission required to test lead candidate BSG005 in patients with invasive fungal infection. | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-06-11 | Biosergen | Biosergen AB: BioStock: Biosergen på väg mot första patientstudien med svampdödande behandling | Pressreleaser | Visa Stäng |
|
||||
2024-06-11 | Biosergen | Biosergen AB: BioStock: Biosergen towards first-in-patient trial with antifungal therapy | Pressreleaser | Visa Stäng |
|
||||
2024-05-31 | Biosergen | Biosergen AB: Biosergen publishes interim report for first quarter 2024 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-05-17 | Biosergen | Notice of annual general meeting in Biosergen AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-05-14 | Biosergen | Biosergen AB: BioStock: Biosergens vd "det är ett globalt hälsohot som kräver handling" | Pressreleaser | Visa Stäng |
|
||||
2024-05-14 | Biosergen | Biosergen AB: BioStock: Biosergen's CEO - "this is a global health threat and it needs attention" | Pressreleaser | Visa Stäng |
|
||||
2024-05-10 | Biosergen | Biosergen AB: Biosergen publishes 2023 annual report | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-16 | Biosergen | Biosergen AB: Conversion of paid subscribed units and first day of trading with warrants of series TO3 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-09 | Biosergen | Biosergen AB: Biosergen resolves on a directed issue to underwriters in connection with the completed rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-26 | Biosergen | Biosergen AB: Biosergen announces the outcome in the rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-18 | Biosergen | Biosergen AB: BioStock Investor Pitch: Biosergen | Pressreleaser | Visa Stäng |
|
||||
2024-03-18 | Biosergen | Biosergen AB: BioStock Investor Pitch: Biosergen | Pressreleaser | Visa Stäng |
|
||||
2024-03-15 | Biosergen | Biosergen AB: Members of the board of directors and management subscribe in ongoing rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-13 | Carlsquare | Carlsquare: Research update Biosergen: Rights issue to fund crucial step for lead project | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-12 | Biosergen | Biosergen AB: BioStock: Emission ska ta Biosergen till första effektdata i människa | Pressreleaser | Visa Stäng |
|
||||
2024-03-12 | Biosergen | Biosergen AB: BioStock: Rights issue to give Biosergen first in-human efficacy data | Pressreleaser | Visa Stäng |
|
||||
2024-03-08 | Biosergen | Biosergen AB: BioStock: Biosergen angriper osynliga hotet från svampinfektioner | Pressreleaser | Visa Stäng |
|
||||
2024-03-08 | Biosergen | Biosergen AB: BioStock: Biosergen attacks invisible threat of fungal infections | Pressreleaser | Visa Stäng |
|
||||
2024-03-07 | Carlsquare | Carlsquare: Carlsquare Equity Research interview with Biosergen | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-07 | Biosergen | Biosergen AB: Biosergens vd till BioStock: "Positiva data ger oss starkt erbjudande" | Pressreleaser | Visa Stäng |
|
||||
2024-03-07 | Biosergen | Biosergen AB: Biosergen CEO to BioStock: "Positive data give us a strong value proposition" | Pressreleaser | Visa Stäng |
|
||||
2024-03-05 | Biosergen | Biosergen AB: Biosergen publishes prospectus due to rights issue of units | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-01 | Biosergen | Bulletin from the extraordinary general meeting in Biosergen AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-29 | Biosergen | Biosergen AB: Biosergen publishes interim report for fourth quarter 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-12 | Biosergen | Biosergen AB: Biosergen receives regulatory approval to test lead candidate BSG005 in patients with invasive fungal infection. | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-02 | Carlsquare | Carlsquare: Mrkt BUZZ, Biosergen: Rights issue to fund the next clinical step | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-01-30 | Biosergen | Notice of Extraordinary general meeting in Biosergen AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-01-30 | Biosergen | Biosergen AB: Biosergen carries out a rights issue of units of approximately SEK 40.5 million, and secures bridge loan | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-01-16 | Carlsquare | Carlsquare: Research Update Biosergen: Licensing deal with Alkem and CTA submission | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-01-12 | Biosergen | Biosergen AB: Biosergen Announces Leadership Transition: Peder M. Andersen to Step Down as CEO, Tine Olesen Appointed as Successor | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-01-12 | Biosergen | Biosergen AB: Biosergen - Indian collaboration gives boost - Mangold Insight Analys | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-12 | Biosergen | Biosergen AB: Biosergen's Partner Alkem Laboratories Submits Clinical Trial Application for First Patient Study with BSG005 in Invasive Fungal Infections in India as a Rescue Therapy | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-11 | Carlsquare | Carlsquare: Biosergen, Carlsquare Nordic life science investor day | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-30 | Biosergen | Biosergen AB: Biosergen publishes interim report for third quarter 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-11-30 | Biosergen | Biosergen AB changes Certified Adviser to Carnegie Investment Bank AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-23 | Biosergen | Biosergen AB: Abstract presented at the 11th Trends in Medical Mycology publicly available | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-09-25 | Biosergen | Biosergen AB: Biosergen and Alkem Laboratories Ltd collaborates to develop anti-infective for severe fungal infections | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-28 | Biosergen | Warrants series TO2 were exercised to approximately 96.1 percent and Biosergen AB receives approximately SEK 5.5 million | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-22 | Biosergen | The last day of trading in warrants series TO2 in Biosergen AB is today, August 22, 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-16 | Carlsquare | Carlsquare: Research Update Biosergen, Q2 2023: Stable in costs but delays in clinical timeline | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-16 | Biosergen | Biosergen AB: Biosergen Receives Full Subscription Guarantees for Warrant Exercise from Largest Shareholders and Executive Management | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-14 | Biosergen | Biosergen AB: Biosergen publishes interim report for first quarter 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-11 | Biosergen | Biosergen AB: The subscription price for warrants series TO2 in Biosergen has been determined to SEK 0.66 and the exercise period starts on August 14, 2023 | Pressreleaser | Ladda ner | Visa Stäng |
Pressreleaser |
Biosergen AB: The subscription price for warrants series TO2 in Biosergen has been determined to SEK 0.66 and the exercise period starts on August 14, 2023Summarized terms for warrants series TO2: Each unit in the Rights Issue consisted of five (5) shares and three (3) warrants series TO2. Each warrant series TO2 entitles to subscription of one (1) new share in the Company. The exercise price for warrants series TO2 has been determined as 70 percent of the volume-weighted average price of the Company’s share on Nasdaq First North Growth Market during the measurement period, which ran from and including July 28, 2023, up to and including August 10, 2023. During the measurement period, the volume-weighted average price in the Company’s share was approximately SEK 0.94, therefore, the exercise price for warrants series TO2 is SEK 0.66. The exercise period for warrants series TO2 runs during the period from and including August 14, 2023, up to and including August 25, 2023. If all warrants series TO2 are exercised, the Company will receive approximately SEK 5.7 million before issuing costs. In order for the warrants not to expire and lose their value, it is required that the holder actively subscribes for new shares no later than August 25, 2023, or sells the warrants no later than August 22, 2023. Please observe that certain nominees might close their application earlier than August 25, 2023. Please note that warrants that are not exercised no later than August 25, 2023, or sold no later than August 22, 2023, will expire without value. For warrants not to lose their value, the holder must actively subscribe for new shares or sell the warrants. How warrants are exercised: Direct-registered warrants (Securities account) The application form including instructions for payment will be available at the Company’s website, www.Biosergen.net. Advisors |
||||
2023-08-11 | Biosergen | Biosergen AB: Biosergen publish financial report for second quarter ahead of schedule. | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-07 | Biosergen | Biosergen AB: Biosergen Announces Abstract Accepted for Presentation at the 11th Congress on Trends in Medical Mycology (TIMM-11) | Pressreleaser | Ladda ner | Visa Stäng |
|